MTOR and cancer: PI3K-Akt-mTOR activation actively participates in key hallmarks of NSCLC, including sustained cancer growth, apoptosis resistance, angiogenesis, cancer invasion and metastasis and insensitivity to therapies [6, 8, 10–12].